106 related articles for article (PubMed ID: 2515915)
1. In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide.
Gulati SC; Kwon JH; Kushner B; Cheung NK; Atzpodien J; Shum K; Clarkson BD
Cancer Invest; 1989; 7(5):417-22. PubMed ID: 2515915
[TBL] [Abstract][Full Text] [Related]
2. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
3. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta 3 protects normal human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide in vitro.
Lemoli RM; Strife A; Clarkson BD; Haley JD; Gulati SC
Exp Hematol; 1992 Dec; 20(11):1252-6. PubMed ID: 1493854
[TBL] [Abstract][Full Text] [Related]
5. In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantation.
Gulati SC; Kwon JH; Atzpodien J; Triche TJ; Colvin OM; Clarkson BD
Cancer Invest; 1989; 7(5):411-6. PubMed ID: 2620246
[TBL] [Abstract][Full Text] [Related]
6. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.
Lemoli RM; Gasparetto C; Scheinberg DA; Moore MA; Clarkson BD; Gulati SC
Blood; 1991 Apr; 77(8):1829-36. PubMed ID: 2015406
[TBL] [Abstract][Full Text] [Related]
7. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow.
Siena S; Castro-Malaspina H; Gulati SC; Lu L; Colvin MO; Clarkson BD; O'Reilly RJ; Moore MA
Blood; 1985 Mar; 65(3):655-62. PubMed ID: 3971044
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies.
Gulati SC; Shimazaki C; Lemoli RM; Atzpodien J; Clarkson BD
Eur J Haematol Suppl; 1989; 51():164-72. PubMed ID: 2627987
[TBL] [Abstract][Full Text] [Related]
9. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
10. Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide.
Rowley SD; Colvin OM; Stuart RK
Exp Hematol; 1985 May; 13(4):295-8. PubMed ID: 3987832
[TBL] [Abstract][Full Text] [Related]
11. Density-gradient separation of autologous bone marrow grafts before ex vivo purging with 4-hydroperoxycyclophosphamide.
Rowley SD; Davis JM; Piantadosi S; Jones RJ; Yeager AM; Santos GW
Bone Marrow Transplant; 1990 Nov; 6(5):321-7. PubMed ID: 2291993
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
Rowley SD; Jones RJ; Piantadosi S; Braine HG; Colvin OM; Davis J; Saral R; Sharkis S; Wingard J; Yeager AM
Blood; 1989 Jul; 74(1):501-6. PubMed ID: 2665843
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
14. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement.
De Fabritiis P; Bregni M; Lipton J; Greenberger J; Nadler L; Rothstein L; Korbling M; Ritz J; Bast RC
Blood; 1985 May; 65(5):1064-70. PubMed ID: 3995166
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells.
Bhalla K; Bullock G; Lutzky J; Holladay C; Ibrado AM; Jasiok M; Singh S
Leukemia; 1992 Aug; 6(8):814-9. PubMed ID: 1640734
[TBL] [Abstract][Full Text] [Related]
16. Ascorbic acid enhances the cytotoxic effect of 6-hydroxydopamine for human neuroblastoma cell lines.
Reynolds CP; Perez-Polo JR
Neurosci Lett; 1981 Oct; 26(2):151-5. PubMed ID: 6795547
[TBL] [Abstract][Full Text] [Related]
17. Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.
Jones RJ; Zuehlsdorf M; Rowley SD; Hilton J; Santos GW; Sensenbrenner LL; Colvin OM
Blood; 1987 Nov; 70(5):1490-4. PubMed ID: 3311205
[TBL] [Abstract][Full Text] [Related]
18. Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Reynolds CP; Reynolds DA; Frenkel EP; Smith RG
Cancer Res; 1982 Apr; 42(4):1331-6. PubMed ID: 7037175
[TBL] [Abstract][Full Text] [Related]
19. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres.
O'Briant KC; Shpall EJ; Houston LL; Peters WP; Bast RC
Cancer; 1991 Sep; 68(6):1272-8. PubMed ID: 1873781
[TBL] [Abstract][Full Text] [Related]
20. Regrowth of granulocyte-macrophage progenitor cells (GM-CFC) in suspension cultures of bone marrow depleted of GM-CFC with 4-hydroperoxycyclophosphamide (4-HC).
Beran M; Zander AR; Andersson BS; McCredie KB
Eur J Haematol; 1987 Aug; 39(2):118-24. PubMed ID: 3666100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
